ReviewJournal of nanobiotechnology2026
Apoptotic extracellular vesicles act as master regulators of the bone healing niche.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Apoptotic extracellular vesicles (ApoEVs), natural bilayer nanoparticles released during programmed cell death, have emerged as pivotal regulators and promising therapeutic agents for bone regeneration. They function as innate multimodal signaling entities, expertly coordinating the complex cellular interplay between osteogenesis, angiogenesis, innervation, and immunomodulation required for successful bone healing. This review systematically outlines the biogenesis, isolation, and fundamental mechanisms by which ApoEVs orchestrate the bone healing niche. We further explore their dual role in bone homeostasis and pathology, highlighting applications in treating osteoporosis and osteoarthritis, while acknowledging potential negative effects from specific cellular origins. The significant promise of ApoEVs is being unlocked through innovative engineering strategies to enhance their therapeutic efficacy and specificity. Critically, we discuss how emerging artificial intelligence (AI) tools are poised to overcome major translational hurdles. Despite the challenges in standardization and scalable production, the convergence of ApoEV biology and AI-driven design positions them as a transformative next-generation, cell-free platform for treating intractable bone and joint disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.